New York, NY – According to filings with the U.S. Securities and Exchange Commission, Schrodinger Inc. is raising $115,000,000.00 in a new round of investment. Sources indicate as part of senior management President and Chief Executive Officer, Ramy Farid played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Schrodinger Inc.

Schrodinger is a leading provider of advanced molecular simulations and enterprise software solutions and services for pharmaceutical, biotechnology, and materials science research. The predictive power of Schrodinger’s software allows scientists to accelerate their research and development, reduce research costs, and make novel discoveries that might otherwise not be possible. Schrodinger also establishes deep partnerships and collaborations with companies in such fields as biotechnology, pharmaceuticals, chemicals, and electronics, and helped found the biotech company Nimbus Therapeutics. Through significant long-term investments in basic research, Schrodinger has made scientific breakthroughs across many areas of drug discovery and materials science. Hundreds of peer-reviewed scientific publications by Schrodinger scientists are frequently among the most heavily cited in their fields. To learn more about Schrodinger Inc., visit http://www.schrodinger.com/

Contact:
Ramy Farid, President and Chief Executive Officer
503-299-1150
ramy.farid@schrodinger.com
https://www.linkedin.com/in/ramyfarid/

SOURCE: http://www.intelligence360.io
Copyright (c) 2019 SI360 Inc. All rights reserved